PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

EJNMMI Research

Table 1 Patient characteristics

Characteristic	Patients
Age (years), median (IQR), n = 186	68 (61–72)
iPSA (ng/ml), median (IQR), n = 184^a	9.7 (6.5–15.1)
Administered ⁶⁸Ga-PSMA-11 activity (MBq), median (IQR), n = 185^b	139 (112–156)
Time PET to RP (day), median (IQR), n = 186	26 (13–46)
Gleason score in surgical specimen, no. (%), n = 186
6	11 (5.9%)
7a	63 (33.9%)
7b	59 (31.7%)
8	28 (15.1%)
9	25 (13.4%)
Pathological stage, no. (%), n = 186
pT status
2a	11 (5.9%)
2b	10 (5.4%)
2c	71 (38.2%)
3a	49 (26.3%)
3b	44 (23.7%)
4	1 (0.5%)
pN status
0	154 (82.8%)
1	32 (17.2%)
Surgical margin, no. (%), n = 180^c
Negative	152 (84.4%)
Positive	28 (15.6%)

iPSA initial PSA, IQR interquartile range, PET positron emission tomography, PSA prostate-specific antigen, RP radical prostatectomy
^aiPSA of two patients were unavailable
^bThe injected dose of ⁶⁸Ga-PSMA-11 from one patient was unavailable
^cThe status of surgical margin from six patients were unavailable